Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 30, 2017
Reporting Period: Event date of November 30, 2017
Business Context: The filing reports a corporate governance amendment adopted by the Board of Directors regarding the election of directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused solely on corporate governance changes.
Material Changes
The Board of Directors adopted amended and restated bylaws effective immediately on November 30, 2017. The primary material change is the implementation of a majority vote standard for the election of directors in non-contested elections. Previously, directors were elected by a plurality of votes cast. Under the new standard, a nominee must receive more votes "for" than "against" to be elected. In contested elections, the plurality standard remains in effect.
Guidance, Outlook, and Management Commentary
Management Commentary: The filing details the procedural change in voting standards and the associated resignation protocol. Under the amended Corporate Governance Guidelines, any director nominee in a non-contested election who receives more votes against than for must offer to resign. The Board will then decide whether to accept or reject the resignation.
Risks and Contingencies: No specific financial risks or contingencies are disclosed in this filing.
Guidance: No financial guidance or outlook is provided.
Important Facts for Investors to Verify
- The effective date of the new majority vote standard is November 30, 2017.
- The change applies only to non-contested director elections; contested elections still use a plurality standard.
- Directors receiving a majority of "against" votes in non-contested elections are required to offer their resignation.
- The full text of the Amended and Restated Bylaws is attached as Exhibit 3.1.
- The company is classified as an emerging growth company.